Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer
21.10.2018 12:10:00 EEST | Business Wire | Press release
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in The Lancet Oncology.
Based on the results, Servier filed a new application for an additional indication for gastric cancer to the European Medicines Agency (EMA) for LONSURF®.
“Patients with metastatic gastric cancer currently have limited treatment options after first and second line therapies have failed,” said Dr. Arkenau. “We are pleased to present new data that demonstrate the overall survival clinical benefit of trifluridine/tipiracil in metastatic gastric and gastroesophageal cancer.”
In TAGS patients treated with trifluridine/tipiracil showed a clinically meaningful and statistically significant improvement in OS compared with placebo and a 31 percent risk reduction of death (HR 0.69 one sided p=0.00029), which translated into a prolonged median survival of 2.1 months (5.7 months for trifluridine/tipiracil versus 3.6 months for placebo). In addition, trifluridine/tipiracil demonstrated a statistically significant improvement in PFS and time to deterioration of ECOG performance status versus placebo, as well as a predictable and manageable safety profile consistent with that previously reported in patients with metastatic colorectal cancer.
“We’re very excited by the results of TAGS as they show trifluridine/tipiracil has the potential to make a difference to the lives of people living with metastatic gastric cancer who continue to struggle with this devastating disease,” said Patrick Therasse, Head of Servier Research and Development Oncology Department.
Trifluridine/tipiracil is currently indicated in 61 countries, including those of the European Union, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.1
The abstract for the trifluridine/tipiracil presentation is available on the ESMO website and the manuscript is published online in The Lancet Oncology.
ENDS
About TAGS
TAGS (
TA
S-102
G
astric
S
tudy)
is a Taiho-sponsored pivotal Phase III, multinational, randomized,
double-blind study evaluating trifluridine/tipiracil, also known as
TAS-102, plus best supportive care (BSC) versus placebo plus BSC in
patients with metastatic gastric cancer, including gastro esophageal
junction cancer, refractory to standard treatments. The primary endpoint
in the TAGS trial is overall survival (OS), and the main secondary
endpoint measures include progression-free survival (PFS), and safety
and tolerability, as well as quality of life.
TAGS enrolled 507 adult patients with metastatic gastric cancer who had previously received at least two prior regimens for advanced disease. The study was conducted in Japan, the United States, the European Union, Russia, Belarus, Israel, and Turkey.
For more information on TAGS, please visit www.ClinicalTrials.gov ( https://clinicaltrials.gov/ct2/show/NCT02500043). The ClinicalTrials.gov Identifier is NCT02500043.
About Metastatic Gastric Cancer
Gastric cancer, also known
as stomach cancer, is a disease in which malignant cells form in the
lining of the stomach. It is the fifth most common cancer worldwide and
the third most common cause of cancer-related death (after lung and
liver cancer), with an estimated 723,000 deaths annually.2
When cancer spreads it is called advanced cancer. Locally advanced cancer is when the cancer has grown outside the organ it started in but hasn’t spread to other parts of the body. When the cancer spreads to other parts of the body this is called metastatic cancer. In the last two decades, the proportion of patients with gastric cancer who present with metastases has risen to over 40%.3
Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, and taxanes (with ramucirumab), or irinotecan. The addition of trastuzumab to chemotherapy is standard of care for patients with HER2-neu-positive advanced gastric cancer. However, after failure of first- and second-line therapies, standard third-line treatments are limited.
About LONSURF
®
(trifluridine and tipiracil,
TAS-102)
LONSURF
®
is an oral anticancer
drug, comprising a combination of trifluridine (FTD) and tipiracil
(TPI), whose dual mechanism of action is designed to maintain clinical
activity. LONSURF
®
is registered in Japan, USA,
European Union, and in many other countries. In the European Union,
LONSURF
®
is indicated for the treatment of adult
patients with metastatic colorectal cancer (CRC) who have been
previously treated with, or are not considered candidates for, available
therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-
based chemotherapies, anti-VEGF agents, and anti-EGFR agents.1
LONSURF ® is recommended by the National Institute for Health and Care Excellence (NICE),4 NCCN5,6 and ESMO Guidelines7 for the treatment of adult patients with metastatic CRC.
In June 2015, Servier and Taiho Pharmaceutical entered into an exclusive license agreement for the co-development and commercialization of LONSURF ® .
As of October 2018, LONSURF ® has been approved as a treatment for mCRC in 61 countries and regions worldwide.
About Servier
Servier is an international pharmaceutical
company governed by a non-profit foundation, with its headquarters in
France (Suresnes). With a strong international presence in 149 countries
and a turnover of 4.152 billion euros in 2017, Servier employs 21,700
people worldwide. Entirely independent, the Group reinvests 25% of its
turnover (excluding generic drugs) in research and development and uses
all its profits for development. Corporate growth is driven by Servier’s
constant search for innovation in five areas of excellence:
cardiovascular, immune-inflammatory and neuropsychiatric diseases,
cancer and diabetes, as well as by its activities in high-quality
generic drugs. Servier also offers eHealth solutions beyond drug
development.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as various leukemias and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, and targeted therapies, to deliver life-changing medicines to patients.
For more information about Servier, please visit www.servier.com .
About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho
Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/),
is an R&D-driven specialty pharma focusing on the three fields of
oncology, allergy and immunology, and urology. Its corporate philosophy
takes the form of a pledge: “We strive to improve human health and
contribute to a society enriched by smiles.” In the field of oncology in
particular, Taiho Pharmaceutical is known as a leading company in Japan
for developing innovative medicines for the treatment of cancer, a
reputation that is rapidly expanding through their extensive global R&D
efforts. In areas other than oncology, as well, the company creates and
markets quality products that effectively treat medical conditions and
can help improve people's quality of life. Always putting customers
first, Taiho Pharmaceutical also aims to offer consumer healthcare
products that support people's efforts to lead fulfilling and rewarding
lives.
For more information about Taiho Pharmaceutical, please visit: https://www.taiho.co.jp/en/.
ENDS
1 EMA. Summary of product characteristics: LONSURF. Available at: https://www.ema.europa.eu/documents/product-information/lonsurf-epar-product-information_en.pdf Accessed October 2018.
2 Ferlay J, Soerjomataram I, Dikshit R, et al. Int J Cancer. 2015;136:E359-86.
3 Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24:3056–60.
4 NICE TA405. Available at: www.nice.org.uk/guidance/TA405 Accessed October 2018.
5 National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
6 National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
7 ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: Van Cutsem E et al. Ann Oncol. 2016;27:1386-422.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181021005023/en/
Contact information
Servier
Sonia MARQUES
media@servier.com
Tél.
+33-(0)1-55-72-40-21 / + 33-(0)-7-84-28-76-13
or
Karine
BOUSSEAU
media@servier.com
Tél.
+33-(0)1-55-72-60-37
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Visa Data Reveals How the FIFA World Cup 2026™ Created Pop-Up Economies Across Canada, Mexico and the United States22.7.2026 14:00:00 EEST | Press release
After the final whistle blew on the FIFA World Cup 2026™, millions of fans returned home with unforgettable memories and a trail of economic activity that stretched across countries. Every tap to pay left a lasting impact, as spending throughout the tournament delivered a meaningful boost to merchants and local economies across host cities in Canada, Mexico and the United States. According to new data from Visa, the tournament drove significant growth in cross-border spending, international travel, and digital commerce across host cities. The findings show how a major global event creates “pop-up economies,” defined by Visa as temporary, highly concentrated periods of commercial activity that emerge around major cultural, entertainment and sporting events. The data reveals that fans traveled from around the world to follow their teams, generating a surge in Visa cardholder spending across restaurants, transportation, entertainment, retail, lodging, and other sectors. From iconic host c
Accertify and Liminal Release First Empirical Study Proving Fraud-Cyber Convergence Works - and Defining How to Do It Right22.7.2026 14:00:00 EEST | Press release
Accertify, a leading fraud decisioning provider whose Predictive Yes Platform enables merchants to say yes to more good customers, more revenue, and more growth, today released The Convergence Dividend: Quantifying What Fraud-Cyber Convergence Actually Delivers, a landmark proprietary study conducted in partnership with Liminal. The research - spanning 250 Director-level and above fraud, risk, and security leaders across Retail/eCommerce, Travel, Restaurants/QSR, Entertainment & Media, and Marketplaces - is the first large-scale empirical proof that fraud-cyber convergence produces better business outcomes, and the first to identify the specific behaviors that separate top-performing organizations from the rest. While fraud-cyber convergence is a nearly unanimous (94%) recognized priority by respondents, the research found that many organizations lack a clear framework for how to operationalize it effectively. To identify the practices associated with the strongest outcomes, Accertify
NIQ and Circle K Expand Global Analytics Collaboration Across More Than 12 Countries22.7.2026 13:00:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, and Circle K today announced a multi-year global agreement spanning more than 12 countries across North America and Europe. The collaboration brings together NIQ’s global scale, AI-powered analytics, and deep local market intelligence to help Circle K transform decision-making, accelerate growth, and deliver best-in-class customer experiences across its expanding global footprint. In an increasingly competitive and fast-changing retail landscape, the collaboration enables Circle K to stay ahead of evolving consumer demand, optimize performance, and unlock new growth opportunities across markets. Through NIQ’s AI-driven insights and decisioning platforms, Circle K’s Business Units and Global Center of Excellence will accelerate smarter merchandising, pricing, and operational decisions—tailored to local market dynamics while aligned to a global strategy. In Europe, the agreement enables Circle K teams to tailor analytics, as
Japan's Cross-Border E-Commerce "WAFUU.COM" Unveils Official Mascot Character "Mochi"22.7.2026 11:00:00 EEST | Press release
QRESTIA Inc. (Headquarters: Shibuya, Tokyo; President & CEO: Hidemasa Fukada) is pleased to announce that WAFUU.COM, its cross-border e-commerce site, has unveiled its new official mascot character, Mochi. Mochi will represent WAFUU.COM's warmth and friendliness across its website, social media, campaigns, package inserts, and other creative materials, connecting with fans everywhere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721435469/en/ Mochi, WAFUU.COM's new official mascot character, embodies "A tiny happiness from Japan." (Photo: WAFUU.COM) The debut video is now live on Mochi's official website: https://mochi.wafuu.com/ 1. About Mochi Mochi was born to embody the simple joy of choosing Japanese products. Its soft, rounded silhouette, gentle expression, and distinctive, endearing details are designed to feel welcoming to first-time visitors and longtime fans of Japanese culture alike — a character people will w
New NEURA Gym with RWTH Aachen: NEURA Robotics Expands its Global Training Network for Physical AI22.7.2026 10:10:00 EEST | Press release
NEURA Robotics ("NEURA"), the pioneer in cognitive robotics and creator of the Neuraverse, today announces a new partnership with RWTH Aachen University for the establishment of NEURA Gym RWTH Aachen. This continues the global rollout of NEURA Gyms, a worldwide network of purpose-built Physical AI training facilities that address the most significant barrier to intelligent robotics: the scarcity of real-world training data. The global rollout is backed by NEURA's Series C financing of up to $1.4 billion, the largest ever raised by a full-stack robotics company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721136838/en/ New NEURA Gym with RWTH Aachen: NEURA Robotics Expands its Global Training Network for Physical AI While ten NEURA Gyms are currently under development, five locations across Europe, the United States and China will be operational by end of 2026. The network is anchored by the two European flagship Univer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
